Rafael Holdings Q4 Net Loss Widens Due to Cyclo Acquisition-Related Expenses

miércoles, 29 de octubre de 2025, 4:38 pm ET1 min de lectura
RFL--

Rafael Holdings reported a wider Q4 net loss due to acquisition-related expenses. The company's interests include clinical and early-stage pharmaceutical companies, a medical device company, and a cannabis company. Rafael also holds investments, including Cyclo Therapeutics, which is developing Trappsol Cyclo. The company has a commercial building in Israel.

Rafael Holdings Q4 Net Loss Widens Due to Cyclo Acquisition-Related Expenses

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios